NEW YORK (GenomeWeb News) – PerkinElmer announced today that it has purchased several radiochemical-related reagent assets from GE Healthcare.

Under the agreement, PerkinElmer will obtain GE Healthcare's 3H and 14C catalog radiochemicals, along with its Scintillation Proximity Assay (SPA) reagents and Cytostar-T plate product lines.

Catalog radiochemicals are used for a variety of research purposes including binding assays that may reveal possible drug candidates. The SPA and Cytostar-T plate products, meanwhile, allow high-throughput screening for such interactions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.